Trial reportFrontiers in immunology2026
Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06356584 (Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases: A Randomized, Controlled, Multicenter Phase II Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic colorectal cancer (mCRC) has limited treatment options beyond the second-line. Accumulating evidence has reported that liver metastases harbor a greater abundance of immunosuppressive cells relative to primary tumors. However, about 70% of mCRC patients have liver metastases, which worsen prognosis and reduce immunotherapy benefits. Local therapies, such as liver-directed radiotherapy, have shown promise in reducing tumor burden and improving survival. Methods: This phase II trial aims to evaluate the efficacy and safety of sintilimab combined with fruquintinib, with or without liver-directed radiotherapy, versus fruquintinib alone in the third-line treatment of colorectal cancer with liver metastases (CRCLM). Patients aged 18-75 years with microsatellite stable CRCLM who have received first- and second-line therapies will be randomized 3:3:2 into intervention, control, and standardized treatment groups. Patients in the intervention group will be given sintilimab plus fruquintinib in combination with liver-directed radiotherapy. For liver oligometastases, stereotactic body radiation therapy (SBRT) will be performed with a dose of 40-50 Gy/5 F, 60-70 Gy/10 F, or 65 Gy/13 F. For multiple liver metastases, SBRT plus low-dose radiation therapy (LDRT) will be performed. The appropriate lesions will be selected to receive SBRT with a dose of 40-50 Gy/5 F, 60-70 Gy/10 F, or 65 Gy/13 F, and the remaining liver lesions will undergo LDRT at a total dose of 1-10 Gy with 0.5-2.0 Gy/F. Patients in the control group will be treated with sintilimab plus fruquintinib, and patients in the standardized treatment group will be treated with fruquintinib only. The primary endpoint is PFS and secondary endpoints are objective response rate, disease control rate, OS, and safety. Discussion: We hypothesize that combining sintilimab with liver-directed radiation therapy on the basis of fruquintinib will enhance disease control and prolong survival compared to treatment with fruquintinib plus sintilimab alone. Clinical Trial Registration: clinicalTrials.gov, identifier (NCT06356584).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.